ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: It is proposed that this biosensor can be used as a diagnostic tool to investigate the activity of BCR-ABL between CML patients and also for high-throughput drug screens for novel BCR-ABL inhibitors.